We came across a bullish thesis on TG Therapeutics Inc (TGTX) on ValueInvestorsClub by Bohr. In this article we will summarize the bulls' thesis on TGTX. TG Therapeutics shares were trading at $14 ...

PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by ...

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment ...

Sorrento Therapeutics faced a financial and legal crisis in February 2023, and needed to file for bankruptcy. The pharmaceutical developer’s chief executive and chief financial officers met with ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Liisa Bayko from Evercore ISI maintained a Buy rating on the ...

TG Therapeutics' Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY, leading to an upgraded full-year guidance of $290-$300 million. Expansion into CAR-T therapy for autoimmune ...

A digital therapeutic (DTx) is defined as “health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a ...

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501 ...

Dyne Therapeutics Inc. 6.03% $3.66B ...